Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015;2(4):371-379.
doi: 10.2217/hep.15.26.

Molecular classification of hepatocellular carcinoma: potential therapeutic implications

Nicolas Goossens  1 , Xiaochen Sun  2 , Yujin Hoshida  2
Affiliations

Molecular classification of hepatocellular carcinoma: potential therapeutic implications

Nicolas Goossens et al. Hepat Oncol. 2015.

Abstract

Genomic profiling of hepatocellular carcinoma (HCC) tumors has elucidated recurrent molecular aberrations common or specific to disease etiology, patient race or geographic regions, allowing the classification of HCC tumors into subclasses sharing similar molecular and clinical characteristics. Previously reported transcriptome-based molecular subclasses have highlighted several common themes. Aggressive tumors are characterized by TP53 inactivation mutations and activation of pro-oncogenic signaling pathways, and further subclassified according to expression of stemness markers. The stemness marker-negative aggressive tumors display preferential TGF-β activation. Another group of less aggressive tumors contains a subclass characterized by CTNNB1 mutations accompanied with overexpression of liver-specific WNT targets such as GLUL. Molecular therapies selectively targeting features of the HCC subclasses have suggested their utility in enriching potential responders in clinical trials and guiding therapeutic decision-making for HCC patients.

Keywords: clinical trial; hepatocellular carcinoma; molecular classification; molecular targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

N Goossens is supported by the FLAGS Foundation, the Nuovo-Soldati Cancer Research Foundation and an advanced training grant from Geneva University Hospital. Y Hoshida is supported by NIH/NIDDK (DK099558), Irma T Hirschl Trust and the Dr Harold and Golden Lamport Research Award. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Figures

<b>Figure 1.</b>
Figure 1.. Molecular classification of HCC and molecular and clinical correlates.
MicroTr: Microtrabecular pattern; SH-HCC: Steatohepatitic hepatocellular carcinoma.
See this image and copyright information in PMC

References

    1. El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? where do we go? Hepatology. 2014;60(5):1767–1775. - PMC - PubMed
    1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 2014;64(1):9–29. - PubMed
    1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245–1255. - PubMed
    1. Llovet JM, Hernandez-Gea V. Hepatocellular carcinoma: reasons for Phase III failure and novel perspectives on trial design. Clin. Cancer Res. 2014;20(8):2072–2079. - PubMed
    1. Noureddin M, Rinella ME. Nonalcoholic fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. Clin. Liver Dis. 2015;19(2):361–379. - PMC - PubMed

LinkOut - more resources